Chardan Capital Issues Pessimistic Outlook for FDMT Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Research analysts at Chardan Capital decreased their FY2025 earnings per share (EPS) estimates for 4D Molecular Therapeutics in a note issued to investors on Tuesday, August 12th. Chardan Capital analyst Y. Livshits now expects that the company will earn ($3.52) per share for the year, down from their prior estimate of ($3.07). Chardan Capital currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.52 million.

Other research analysts have also issued reports about the company. Roth Capital dropped their price objective on 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Barclays dropped their price objective on 4D Molecular Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a research note on Friday, May 9th. The Goldman Sachs Group dropped their price objective on 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Thursday. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.40.

4D Molecular Therapeutics Price Performance

4D Molecular Therapeutics stock opened at $7.26 on Friday. The stock has a fifty day moving average price of $4.68 and a two-hundred day moving average price of $4.14. 4D Molecular Therapeutics has a 52-week low of $2.23 and a 52-week high of $17.41. The firm has a market capitalization of $339.04 million, a P/E ratio of -2.06 and a beta of 2.83.

Institutional Trading of 4D Molecular Therapeutics

Several large investors have recently made changes to their positions in the business. Rangeley Capital LLC bought a new stake in shares of 4D Molecular Therapeutics during the second quarter worth $48,000. Man Group plc boosted its holdings in 4D Molecular Therapeutics by 159.7% in the second quarter. Man Group plc now owns 134,932 shares of the company’s stock valued at $501,000 after acquiring an additional 82,980 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in 4D Molecular Therapeutics by 128.5% in the second quarter. BNP Paribas Financial Markets now owns 63,914 shares of the company’s stock valued at $237,000 after acquiring an additional 35,948 shares during the last quarter. Bridgeway Capital Management LLC boosted its holdings in 4D Molecular Therapeutics by 100.3% in the second quarter. Bridgeway Capital Management LLC now owns 25,000 shares of the company’s stock valued at $93,000 after acquiring an additional 12,516 shares during the last quarter. Finally, BVF Inc. IL boosted its holdings in 4D Molecular Therapeutics by 1.5% in the second quarter. BVF Inc. IL now owns 4,629,289 shares of the company’s stock valued at $17,175,000 after acquiring an additional 68,000 shares during the last quarter. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.